Axa raised its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 214,669 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,399 shares during the period. Axa owned approximately 0.42% of Supernus Pharmaceuticals worth $9,252,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. grew its stake in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock valued at $209,595,000 after acquiring an additional 6,692,025 shares during the period. Vanguard Group Inc. boosted its position in shares of Supernus Pharmaceuticals by 6.6% during the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock valued at $78,762,000 after buying an additional 156,094 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Supernus Pharmaceuticals by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock valued at $52,236,000 after buying an additional 78,084 shares during the last quarter. Ranger Investment Management L.P. boosted its position in shares of Supernus Pharmaceuticals by 2.8% during the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock valued at $46,403,000 after buying an additional 40,131 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in shares of Supernus Pharmaceuticals by 24.5% during the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock valued at $58,675,000 after buying an additional 267,971 shares during the last quarter. 95.38% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Stefan K.F. Schwabe sold 95,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total value of $4,426,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total value of $114,764.40. Following the completion of the sale, the vice president now owns 24,944 shares in the company, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. Insiders sold a total of 160,000 shares of company stock worth $7,505,574 in the last 90 days. 6.70% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/13/axa-increases-holdings-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals, Inc. (SUPN) opened at 48.35 on Wednesday. The company’s 50 day moving average price is $43.68 and its 200 day moving average price is $37.06. Supernus Pharmaceuticals, Inc. has a 12 month low of $17.25 and a 12 month high of $49.95. The stock has a market cap of $2.45 billion, a PE ratio of 24.39 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. Equities analysts forecast that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current fiscal year.

Several research analysts recently issued reports on the company. Piper Jaffray Companies reaffirmed a “hold” rating and set a $45.00 target price on shares of Supernus Pharmaceuticals in a research report on Friday, September 8th. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Cowen and Company reaffirmed a “positive” rating and set a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 3rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.29.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.